Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
50.4 GBX | +0.80% | 0.00% | -13.19% |
04-24 | Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results | CI |
04-22 | Capital & Regional picks Gerry Murphy as non-exec director | AN |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Commercial REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.19% | 136M | B- | ||
-0.20% | 46.38B | B | ||
-13.75% | 12.39B | A- | ||
-22.92% | 11.06B | A- | ||
-13.01% | 10.74B | A- | ||
-5.43% | 7.45B | C+ | ||
-6.66% | 6.54B | A- | ||
-8.23% | 5.8B | C- | ||
-6.86% | 5.6B | B+ | ||
-7.00% | 4.67B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAL Stock
- Ratings Capital & Regional plc